viewAusCann Group Holdings Ltd
The company recently appointed Canadian Luke Pigeau as master grower.
() has been granted a trading halt by the ASX pending the release of information regarding a capital raising.
Shares in the company will remain halted until the earlier of the release of the relevant information or the commencement of trading on Thursday.
READ: AusCann Group Holdings to accelerate medical cannabis strategy through master grower appointment
Last week AusCann outlined that it intended to accelerate its Australian medical cannabis manufacturing operation through the appointment of Canadian Luke Pigeau as master grower.
Pigeau, who was appointed following an extensive global search, will oversee AusCann’s Tasmanian Alkaloids cultivation operation in Tasmania.
The appointment is complemented by the company entering into a research and development agreement with Canadian group Jade Cannabis.
ASX:AC8
Market: ASX
Market Cap: $93.53 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Auscann targeting pain management with Australian cannabinoid products
Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....
on 09/05/2018
2 min read
Prev article
2 min read
